Literature DB >> 15013109

Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis.

Karen Hogg1, Karl Swedberg, John McMurray.   

Abstract

Recent cross-sectional, population-based echocardiographic studies show that about half of all patients with heart failure have preserved left ventricular systolic function (HF-PSF). Cohort studies of hospitalized patients show a smaller proportion of HF-PSF. Compared to those with reduced systolic function, patients with HF-PSF are more often female, older, less likely to have coronary artery disease, and more likely to have hypertension. Patients with HF-PSF are less symptomatic and receive different pharmacologic therapy than patients with reduced systolic function. Morbidity and mortality rates in patients with HF-PSF are high but not quite as high as in patients with reduced systolic function. Though much has recently been learned about the syndrome of HF-PSF, many questions remain to be answered, not least how it should be treated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013109     DOI: 10.1016/j.jacc.2003.07.046

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  186 in total

1.  Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

Authors:  Sameer Ather; Wenyaw Chan; Biykem Bozkurt; David Aguilar; Kumudha Ramasubbu; Amit A Zachariah; Xander H T Wehrens; Anita Deswal
Journal:  J Am Coll Cardiol       Date:  2012-03-13       Impact factor: 24.094

2.  Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients.

Authors:  Guangxi Li; Sonal Rachmale; Marija Kojicic; Khurram Shahjehan; Michael Malinchoc; Daryl J Kor; Ognjen Gajic
Journal:  Transfusion       Date:  2010-08-17       Impact factor: 3.157

3.  The natural history of preclinical diastolic dysfunction: a population-based study.

Authors:  Mark W Vogel; Joshua P Slusser; David O Hodge; Horng H Chen
Journal:  Circ Heart Fail       Date:  2012-01-25       Impact factor: 8.790

4.  Symptoms and fear in heart failure patients approaching end of life: a mixed methods study.

Authors:  Martha Abshire; Jiayun Xu; Cheryl Dennison Himmelfarb; Patricia Davidson; Daniel Sulmasy; Joan Kub; Mark Hughes; Marie Nolan
Journal:  J Clin Nurs       Date:  2015-09-25       Impact factor: 3.036

5.  [Guidelines for therapy of chronic heart failure].

Authors:  U C Hoppe; M Böhm; R Dietz; P Hanrath; H K Kroemer; A Osterspey; A A Schmaltz; E Erdmann
Journal:  Z Kardiol       Date:  2005-08

6.  Trends in prevalence of comorbidities in heart failure clinical trials.

Authors:  Muhammad Shahzeb Khan; Ayman Samman Tahhan; Muthiah Vaduganathan; Stephen J Greene; Alaaeddin Alrohaibani; Stefan D Anker; Orly Vardeny; Gregg C Fonarow; Javed Butler
Journal:  Eur J Heart Fail       Date:  2020-04-15       Impact factor: 15.534

7.  Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]).

Authors:  Robert J Goldberg; Jerry H Gurwitz; Jane S Saczynski; Grace Hsu; David D McManus; David J Magid; David H Smith; Alan S Go
Journal:  Am J Cardiol       Date:  2013-02-01       Impact factor: 2.778

8.  Prevalence of suspected diastolic dysfunction in patients with a clinical diagnosis of congestive heart failure.

Authors:  Mohammad-Reza Movahed; Mastaneh Ahmadi-Kashani; Yuji Saito
Journal:  Heart Fail Rev       Date:  2005-12       Impact factor: 4.214

9.  Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis.

Authors:  Ali Ahmed; Gilbert J Perry; Jerome L Fleg; Thomas E Love; David C Goff; Dalane W Kitzman
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

Review 10.  Heart failure and kidney dysfunction: epidemiology, mechanisms and management.

Authors:  Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.